Ottawa, Ontario, Canada, Nov. 10, 2022 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be participating in Europe’s biggest dedicated healthcare investment week.
On November 14th, Anatole Klepatsky (COO), Dr. Oliver Hartley (VP Drug Discovery), and Dr. Ian McGowan (CMO) will be in London to connect with investment partners at the LSX Investival Showcase.
The Orion team will remain in London to attend the Jefferies Healthcare Conference from November 15th–17th. During this time, they will be available for meetings with institutional investors and thought leaders in the biotechnology and pharmaceutical sectors.
To learn more about Orion’s approach to GPCR drug discovery, you can schedule a meeting through the conference partnering platforms.
